Assam free from high MMR burden, infant mortality rate also down: CM
1
2
Guwahati: Assam CM Himanta Biswa Sarma on Thursday said the state has come out from the historical backlog of high burden of maternal mortality ratio (MMR), which has been recorded by the sample registration survey (SRS) special bulletin for 2020-22, released recently.
He added that the state's infant mortality rate (IMR) and under-5 mortality ratio (U5MR) have also improved significantly.
"Assam is no longer the state with the highest MMR in the country. Assam's MMR is now better than Madhya Pradesh (159), Chhattisgarh (141), Uttar Pradesh (141) and Odisha (136) as per SRS 2020-22," Sarma said.
As per SRS 2020-22, MMR of Assam has come down to 125. "This shows, 70 points (36%) drop in MMR in just two years.
No other states in the country have shown such decline," Sarma added.
He said from MMR of 490 in 2001-03, Assam improved to 125 by 2020-22, "almost reducing MMR to 1/4th. It is a great achievement for the state of Assam to bring such a great reduction of MMR even during the period of the Covid-19 pandemic."
He attributed this high historical MMR to poor maternal health conditions and health infrastructure in the state.
"Now, it is time to move forward and capitalise on all our effective strategies.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Scam Exposed: What They Won't Tell You about zero trust!
Expertinspector
Click Here
Undo
We must push Assam towards one of the five best states in the country in health sector," Sarma said, acknowledging that the state still has a great distance to go.
"With renewed commitment and by adopting focused strategies for improvement of health sector with collective efforts of all members of health and family welfare department, medical education and research department, NHM and all other related departments we shall achieve our goals," he said.
"In the last two decades, tremendous efforts have been undertaken, especially in the last 10 years, for which, significant improvement has been observed in reduction of maternal mortality," he said.
He said it is not just MMR, but IMR also has improved tremendously. "Now, our performance (IMR) is at par with Odisha (32) and better than Uttar Pradesh (38), Chattisgarh (38) and Madhya Pradesh (40)," Sarma said.
"Our Under 5 Mortality Rate (U5MR) was as high as 88 per 1000 live births in 2008. This has also come down from 40 (SRS 2020) to 37 (SRS 2021) and further down to 35 (SRS 2022), almost reducing to 1/3rd. Similarly, our neonatal mortality rate also has improved from 33 per 1000 live births in 2005 to 22 in 2020-22," he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
A game-changer in cancer research? South Korean scientists reprogram tumour cells without chemotherapy or radiation
Cancer cells In what may signal the start of a new era in cancer therapy, South Korean researchers at KAIST (Korea Advanced Institute of Science and Technology) have come up with a way to reprogram cancer cells into normal, healthy cells using chemotherapy and radiation-free techniques. The discovery, published recently in Advanced Science, has left the worldwide medical fraternity stunned and has renewed hope for patients whose cancer treatments involve gruelling chemotherapies. Turning cancer cells good? Scientists say it's now possible Classic cancer therapies usually carry agonising side effects and destruction of adjacent normal tissues. Chemotherapy and radiation aim to destroy cancer cells, but they're brutal and can sap the body's strength. What is most revolutionary about this new technique is that it doesn't kill cancer cells; it reprograms them. Using a computer system named BENEIN (Boolean Network Inference), the KAIST researchers were able to map the genetic circuitry of colon cancer cells and essentially "reprogram" them to act like normal cells. BENEIN: The AI-powered tool that reprogrammed cancer cells to normal cells BENEIN functions by studying how genes communicate with each other within cancer cells. Once it knows the network, it selects the most influential genes that regulate the identity of the cell. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo In this situation, the researchers established that silencing three particular genes - MYB, HDAC2, and FOXA2 was sufficient to revert the cancerous nature of the cells. What's more astonishing is that the technique worked in both animal models and lab-grown cells. The cells of colon cancer treated with this procedure began to exhibit normal differentiation, and tumours significantly reduced in size when they were tested in mice. Chemotherapy and radiation Real signs of recovery: What the lab tests showed Not only did the research team observe changes in cell behaviour, but they also followed them down to the molecular level. The cancer cells treated with HDACi started expressing markers characteristic of healthy intestinal cells, including KRT20 and VDR, and turning off cancer-initiating pathways like MYC and WNT. The gene expression of the re-converted cells closely resembled healthy tissue samples included in The Cancer Genome Atlas, further validating the results. Could this become a universal cancer treatment ? Although the advance is focused on colorectal cancer, the potential is far greater than one disease. Because BENEIN is an AI and gene network-based approach, in principle, it is possible to use it against other cancers. But the researchers are warning against overconfidence and caution that additional testing is required before bringing the technique to human clinical trials. Nevertheless, the thought of reprogramming cancer cells rather than killing them is providing entirely new horizons for safer, more personalised treatment. What's next for cancer research ? The study has already positioned KAIST's team at the forefront of non-toxic cancer therapy research. Experts believe that this approach could eventually reduce dependence on chemo and radiation, especially in early-stage cancers. If future clinical trials prove successful, this could be one of the biggest shifts in oncology in decades. One step to a healthier you—join Times Health+ Yoga and feel the change
Time of India
an hour ago
- Time of India
Aakaar Medical Technologies IPO: Check issue size, price band and other details
The initial public offering (IPO) of aesthetic healthcare product maker Aakaar Medical Technologies Limited opens for subscription today, June 20, and will close on June 24, 2025. The company is looking to raise Rs 27 crore through a fresh issue of 37.5 lakh equity shares, with the shares set to list on NSE SME on June 27, subject to allotment finalisation on June 25. The price band for the IPO is Rs 68 to Rs 72 per share, and investors can bid for a minimum lot size of 1,600 shares. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo Ahead of the IPO, the company has raised Rs 7.68 crore from anchor investors by allocating 10.67 lakh shares on June 19. The issue has been structured with 47.42% reserved for qualified institutional buyers (QIBs), 14.29% for non-institutional investors (NIIs), and 33.26% for retail investors. Indorient Financial Services is acting as the book-running lead manager, while Bigshare Services is the registrar to the issue. Alacrity Securities is the designated market maker. Founded in 2013, Aakaar Medical Technologies operates in the medical aesthetics space, supplying dermatology and cosmetic products to physicians, surgeons, and cosmetologists. Its product mix includes skin care, hair care, injectables, laser and aesthetic devices, and home-use products, including solutions for hair loss and pigmentation. Live Events The company distributes both domestically manufactured and imported products from countries like South Korea, Spain, Italy, and Austria, with a presence in over 15 Indian states. It has a dedicated team of 90 sales and service professionals. Financially, Aakaar reported a 33% increase in revenue to Rs 61.76 crore and 110% jump in net profit to Rs 6.04 crore in FY25. The IPO proceeds will be used primarily to meet working capital requirements and for general corporate purposes.
Time of India
an hour ago
- Time of India
Policy shift: Health cover rates vary across states
MUMBAI: With healthcare costs varying widely across Indian states, insurers are shifting away from uniform pricing toward region-specific health policies. Bajaj Allianz General Insurance has launched customised state-wise health insurance plans, adjusting premiums and benefits to reflect local medical costs, infrastructure, and regulations. Bajaj Allianz General Insurance's initiative is designed to address inefficiencies in traditional one-size-fits-all pricing. "The idea behind this cover is to increase coverage of the missing-middle by making health insurance more affordable for them," said Bhaskar Nerurkar, head of health administration at Bajaj Allianz General Insurance. "At present, there is an element of cross-subsidy where people in areas with low-cost healthcare end up subsidising for those with higher costs. " Narayana Health was among the first to offer region-specific policies linked to its hospitals. Bajaj Allianz General Insurance takes this further by refining prices at the state level. While policies are sold based on current residence, policyholders can still receive treatment anywhere in the country. "Regional variations in healthcare claims frequency and severity across India are significantly influenced by diverse factors, including the specific causes for hospitalization," said Satish Gidugu, CEO of Medi Assist, the largest third-party administrator. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Scam Exposed: What They Won't Tell You about zero trust! Expertinspector Click Here Undo "The heightened concentration of tertiary and quaternary care facilities and the greater incidence of claims within Tier-1 cities further accentuate these regional disparities." He added that insurers can now leverage improved data accessibility to more precisely customize their offerings. BAGIC's plans cover all states and UTs, factoring in local disease patterns, hospital charges, and govt scheme implementation. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
